In this Annual Report on Form 10-K, unless otherwise indicated or the context otherwise requires, all references to we, our, us, Centessa, the Company, and our Company refer to Centessa Pharmaceuticals plc and its consolidated subsidiaries. Overview We are a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. We are developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned...
Q2 FY2026 — expected 2026-08-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001847903-26-000025 | EDGAR | 114K words |
| 2025-03-24 | 2024-12-31 | 0001847903-25-000051 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0001847903-24-000054 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0001847903-23-000063 | EDGAR | — |
| 2022-03-30 | 2021-12-31 | 0001847903-22-000022 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001847903-25-000156 | EDGAR | 74K words |
| 2025-08-12 | 2025-06-30 | 0001847903-25-000135 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001847903-25-000072 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001847903-24-000167 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001847903-24-000128 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001847903-24-000081 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001847903-23-000189 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001847903-23-000155 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001847903-23-000097 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001847903-22-000084 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001847903-22-000049 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001847903-22-000031 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001193125-26-134656 | EDGAR | 75K words |
| 2026-02-13 | 0001193125-26-051424 | EDGAR | — |
| 2025-12-11 | 0001193125-25-315074 | EDGAR | — |
| 2025-11-24 | 0001193125-25-292015 | EDGAR | — |
| 2025-11-13 | 0001193125-25-278827 | EDGAR | — |
| 2025-11-05 | 0001847903-25-000154 | EDGAR | — |
| 2025-08-12 | 0001847903-25-000133 | EDGAR | — |
| 2025-06-20 | 0001847903-25-000093 | EDGAR | — |
| 2025-06-17 | 0001847903-25-000090 | EDGAR | — |
| 2025-05-29 | 0001847903-25-000081 | EDGAR | — |
103 total filings indexed. 76 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001847903 |
| Ticker | CNTA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | X0 |
| Website | https://www.centessa.com |
| Listed | 2021-05-28 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report